Joint Filing AgreementJoint Filing Agreement • April 30th, 2004 • Ra Investment Group • In vitro & in vivo diagnostic substances
Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, each of the parties to this Joint Filing Agreement (this “Agreement”) agrees that the statement on Schedule 13G with respect to the Common Stock, par value $0.02 issued by NeoRx Corporation, to which this Agreement is attached as an Exhibit, is filed on behalf of each such party and that any amendments to the attached Schedule 13G will likewise be filed on behalf of each such party.
